Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$64.0 - $116.06 $3.83 Million - $6.94 Million
-59,800 Reduced 89.52%
7,000 $469,000
Q2 2024

Aug 14, 2024

BUY
$110.31 - $140.45 $6.82 Million - $8.68 Million
61,800 Added 1236.0%
66,800 $7.57 Million
Q1 2024

Nov 05, 2024

SELL
$114.22 - $140.1 $7.06 Million - $8.66 Million
-61,800 Reduced 92.51%
5,000 $693,000
Q1 2024

May 15, 2024

BUY
$114.22 - $140.1 $571,100 - $700,500
5,000 New
5,000 $693,000
Q3 2023

Nov 14, 2023

BUY
$86.06 - $137.93 $4.91 Million - $7.88 Million
57,100 New
57,100 $5.33 Million
Q4 2021

Feb 14, 2022

SELL
$129.87 - $162.82 $77,922 - $97,692
-600 Reduced 50.0%
600 $322,000
Q2 2021

Aug 16, 2021

BUY
$80.99 - $107.93 $97,188 - $129,516
1,200 New
1,200 $512,000

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $29.5B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.